Abstracts Archive - Page 993 of 2607 - ACR Meeting Abstracts

Abstract Number: 793 • 2019 ACR/ARP Annual Meeting
Rituximab for Rapidly Progressive Juvenile Systemic Sclerosis: A Proof-of-concept Study in Four Patients
Roberto Dal Pozzolo ¹, Alessandra Meneghel ¹, Biagio Castaldi ¹, Giorgia Martini ¹, Renzo Marcolongo ² and Francesco Zulian³, ¹Dept. of Woman's and Child's Health, University of Padua, Italy, Padua, Italy, ²Clinical Immunology, Dept. of Medicine, University of Padua, Padua, Italy, ³Department of Woman and Child Health, University of Padua, Italy, Padova, Italy
Background/Purpose: Juvenile Systemic Sclerosis (JSSc) is a rare multi-systemic disease characterized by fibrous changes of the skin and internal organs [1]. Patients with “rapidly progressive”…
Abstract Number: 794 • 2019 ACR/ARP Annual Meeting
Mycophenolate Mofetil for the Treatment of Severe or Methotrexate-refractory Juvenile Localized Scleroderma
Laura Saggioro ¹, Giorgia Martini ¹, Roberta Culpo ¹, Alessandra Meneghel ¹ and Francesco Zulian², ¹Dept. of Woman's and Child's Health, University of Padua, Italy, Padua, Italy, ²Department of Woman and Child Health, University of Padua, Italy, Padova, Italy
Background/Purpose: Juvenile Localized Scleroderma (JLS), includes a number of conditions characterized by skin thickening with varying degree of severity. Many patients, particularly those with the…
Abstract Number: 795 • 2019 ACR/ARP Annual Meeting
Is the Presentation and Severity Different of the Juvenile Diffuse and Limited Subtype Systemic Sclerosis? Results of Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche ², Ozgur Kasapcopur ³, Amra Adrovic ⁴, Kathryn Torok ⁵, Valda Stanevicha ⁶, Maria Teresa Terreri ⁷, Flavio Sztajnbok ⁸, Ekaterina Alexeeva ⁹, Jordi Antón ¹⁰, Brian Feldman ¹¹, Maria Katsicas ¹², Vanessa Smith ¹³, Tadej Avcin ¹⁴, Rolando Cimaz ¹⁵, Mikhail Kostik ¹⁶, Thomas Lehman ¹⁷, Walter Sifuentes-Giraldo ¹⁸, Natalia Vasquez-Canizares ¹⁹, Simone Appenzeller ²⁰, Mahesh Janarthanan ²¹, Monika Moll ²², Dana Nemcova ²³, Maria José Santos ²⁴, Dieneke Schonenberg ²⁵, Christina Battagliotti ²⁶, Lillemor Berntson ²⁷, Blanca Bica ²⁸, Juergen Brunner ²⁹, Patricia Costa Reis ³⁰, Despina Eleftheriou ³¹, Liora Harel ³², Gerd Horneff ³³, Tilmann Kallinich ³⁴, Dragana Lazarevic ³⁵, Kirsten Minden ³⁶, Susan Nielsen ³⁷, Farzana Nuruzzaman ³⁸, Anjali Patwardhan ³⁹, Yosef Uziel ⁴⁰, Daniela Kaiser ⁴¹ and Nicola Helmus ¹, ¹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, ⁴Cerrahpaşa Tıp Fakültesi, Istanbul, Turkey, ⁵UPMC Children's Hospital of Pittsburgh, Pittsburgh, ⁶Riga Stradins University, Riga, Latvia, ⁷Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ⁸Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹National Medical Research Center of Children`s Health, Moscow, Russia, ¹⁰Hospital Sant Joan de Déu, Barcelona, Spain, ¹¹University of Toronto & The Hospital for Sick Children, Toronto, ON, Canada, ¹²Hospital de Pediatria, Buenos Aires, Argentina, ¹³Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium, Gent, Belgium, ¹⁴Ljubljana University Medical Centre, Ljubljana, Slovenia, ¹⁵University Hospital Meyer, Florence, Italy, ¹⁶Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, ¹⁷Hospital for Special Surgery, New York, ¹⁸Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁹Children’s Hospital at Montefiore, Bronx NY, ²⁰UNICAMP Universidade Estadual de Campinas, Sao Paulo, Brazil, ²¹Sri Ramachandra University, Chennai, India, ²²University of Tuebingen, Tuebingen, Germany, ²³General University Hospital, Prague, Czech Republic, ²⁴Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ²⁵Amsterdam UMC, Amsterdam, Netherlands, ²⁶Children's Hospital Dr. Orlando Alassia, Santa Fee, Argentina, ²⁷Uppsala University Hospital, Uppsala, Sweden, ²⁸Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ), Rio de Janeiro, Brazil, ²⁹Tirol Kliniken, Innsbruck, Austria, ³⁰Hospital de Santa Maria, Lisbon, Portugal, ³¹Great Ormond Street Hospital, London, United Kingdom, ³²Tel Aviv University, Tel Aviv, Israel, ³³Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ³⁴Charite, Berlin, Germany, ³⁵KC Niš, Niš, Serbia, ³⁶German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ³⁷Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhavn, Denmark, ³⁸Stony Brook Children's Hospital, Stony Brook, NY, ³⁹University of Missouri, Columbia, ⁴⁰Meir Medical Center, Kfar Saba, Israel, ⁴¹Luzerner Kantonsspital | Kinderspital, Luzern, Switzerland
Background/Purpose: Juvenile systemic scleroderma (jSSc) is an orphan disease with an estimated prevalence of 1 in 1 000 000 children. In the adult systemic scleroderma…
Abstract Number: 796 • 2019 ACR/ARP Annual Meeting
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests: Results from the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Bernd Hinrichs ², Kathryn Torok ³, Maria José Santos ⁴, Ozgur Kasapcopur ⁵, Amra Adrovic ⁶, Valda Stanevicha ⁷, Flavio Sztajnbok ⁸, Maria Teresa Terreri ⁹, Ekaterina Alexeeva ¹⁰, Jordi Antón ¹¹, Maria Katsicas ¹², Vanessa Smith ¹³, Tadej Avcin ¹⁴, Rolando Cimaz ¹⁵, Mikhail Kostik ¹⁶, Thomas Lehman ¹⁷, Walter Sifuentes-Giraldo ¹⁸, Simone Appenzeller ¹⁹, Mahesh Janarthanan ²⁰, Monika Moll ²¹, Dana Nemcova ²², Dieneke Schonenberg ²³, Christina Battagliotti ²⁴, Lillemor Berntson ²⁵, Blanca Bica ²⁶, Juergen Brunner ²⁷, Patricia Costa Reis ²⁸, Despina Eleftheriou ²⁹, Liora Harel ³⁰, Gerd Horneff ³¹, Tilmann Kallinich ³², Dragana Lazarevic ³³, Kirsten Minden ³⁴, Susan Nielsen ³⁵, Farzana Nuruzzaman ³⁶, Anjali Patwardhan ³⁷, Yosef Uziel ³⁸ and Nicola Helmus ¹, ¹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany, ²Asklepios Klinik Nord - Heidberg, Hamburg, Germany, ³UPMC Children's Hospital of Pittsburgh, Pittsburgh, ⁴Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁵Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, ⁶Cerrahpaşa Tıp Fakültesi, Istanbul, Turkey, ⁷Riga Stradins University, Riga, Latvia, ⁸Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ¹⁰National Medical Research Center of Children`s Health, Moscow, Russia, ¹¹Hospital Sant Joan de Déu, Barcelona, Spain, ¹²Hospital de Pediatria, Buenos Aires, Argentina, ¹³Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium, Gent, Belgium, ¹⁴Ljubljana University Medical Centre, Ljubljana, Slovenia, ¹⁵University Hospital Meyer, Florence, Italy, ¹⁶Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, ¹⁷Hospital for Special Surgery, New York, ¹⁸Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁹UNICAMP Universidade Estadual de Campinas, Sao Paulo, Brazil, ²⁰Sri Ramachandra University, Chennai, India, ²¹University of Tuebingen, Tuebingen, Germany, ²²General University Hospital, Prague, Czech Republic, ²³Amsterdam UMC, Amsterdam, Netherlands, ²⁴Children's Hospital Dr. Orlando Alassia, Santa Fee, Argentina, ²⁵Uppsala University Hospital, Uppsala, Sweden, ²⁶Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ), Rio de Janeiro, Brazil, ²⁷Tirol Kliniken, Innsbruck, Austria, ²⁸Hospital de Santa Maria, Lisbon, Portugal, ²⁹Great Ormond Street Hospital, London, United Kingdom, ³⁰Tel Aviv University, Tel Aviv, Israel, ³¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ³²Charite, Berlin, Germany, ³³KC Niš, Niš, Serbia, ³⁴German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ³⁵Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhavn, Denmark, ³⁶Stony Brook Children's Hospital, Stony Brook, NY, ³⁷University of Missouri, Columbia, ³⁸Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Juvenile systemic sclerosis(jSSc) is an orphan disease with a prevalence in around 3 in a million children[1]. Pulmonary involvement in jSSc occurs in approximately 40…
Abstract Number: 797 • 2019 ACR/ARP Annual Meeting
Characteristics of Coexisting Localized Scleroderma and Juvenile Idiopathic Arthritis
Daniel Reiff¹, Courtney Crayne ², Melissa Mannion ³ and Randy Cron ¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³University of Alabama at Birmingham, Alabama
Background/Purpose: Localized scleroderma (LS), including morphea and linear scleroderma, is an autoimmune disease where excessive collagen deposits underneath the skin lead to thickening, scarring, and…
Abstract Number: 798 • 2019 ACR/ARP Annual Meeting
Development of Large Vessel Vasculitis Including Aortitis in a Patient with Deficiency of the IL-1 Receptor Antagonist (DIRA) Points to Converging Roles of IL-1 and TNF in Vascular Pathogenesis Recapitulating Findings from a Murine Model
Gina Montealegre Sanchez¹, Adriana de Jesus ¹, Jenna Wade ², Katherine Townsend ¹, Arianne Soldatos ³, Alessandra Brofferio ⁴, Peter C. Grayson ⁵, Ginger Janow ⁶ and Raphaela Goldbach-Mansky ¹, ¹Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, ²Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, ³NIH/NINDS, Bethesda, ⁴NIH/NHLBI, Bethesda, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁶Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, NJ
Background/Purpose: Deficiency of interleukin-1-receptor antagonist (DIRA) is a rare autoinflammatory disease caused by autosomal recessive loss of function mutations in IL1RN and characterized by early-onset generalized pustulosis,…
Abstract Number: 799 • 2019 ACR/ARP Annual Meeting
Application of the Autoinflammatory Disease Activity Index (ADDI) to a Cohort of Patients in a Tertiary Hospital
Mireia Lopez-corbeto¹ and Estefania Moreno Ruzafa ¹, ¹Hospital Universitari Vall d'Hebron, Barcelona, Spain
Background/Purpose: Autoinflammatory diseases (AIDs) cause chronic systemic inflammation that can damage multiple organs. Recently, the ADDI index has been developed and validated in the four…
Abstract Number: 800 • 2019 ACR/ARP Annual Meeting
Cryopyrin-Associated Periodic Syndrome in Korea: 19 Years of Experience
Young Ho Kim¹, Bongjik Kim ², Byung Yoon Choi ², Haeng Jin Lee ³, Dae-Chul Jeong ⁴, Jinhee Han ², Hye-Rim Park ², Jayoung Oh ², Seungmin Lee ², Dooyi Oh ⁵ and Soyoung Lee ¹, ¹Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ²Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital, Seongnam, Kyonggi-do, Republic of Korea, ³Department of Ophthalmology, Seoul National University Hospital, Seoul, Republic of Korea, ⁴Department of Pediatrics, The Catholic University of Korea, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁵Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital, Seoul, Kyonggi-do, Republic of Korea
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) is rare auto-inflammatory disorder characterized by recurrent episodes fever with variable manifestation of systemic inflammation such as urticarial skin rash,…
Abstract Number: 801 • 2019 ACR/ARP Annual Meeting
Preliminary Analysis of Hearing Loss in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed over a Mean of 10 Years: Normal Hearing at Baseline and Early Treatment with Anakinra Area Associated with Maintenance of Normal Hearing
Sara Alehashemi¹, Megha Garg ², Kelly King ³, Chris Zalewski ³, Adriana de Jesus ⁴, John Butman ⁵, Jonah Eisenberg ⁶, Carmen Brewer ³, Jeffrey KIm ⁷ and Raphaela Goldbach-Mansky ¹, ¹Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, MD, ²Rochester Regional Health, Rochester, NY, ³NIDCD/NIH, Bethesda, ⁴Translation Autoinflammatory Diseases Section/NIAID/NIH, Silver Spring, MD, ⁵CC/NIH, Bethesda, ⁶University of Michigan, Ann Arbor, ⁷NIDCD, Bethesda
Background/Purpose: Neonatal-onset multisystem inflammatory disease (NOMID), caused by gain-of-function mutation in the NLRP3 inflammasome, presents with systemic inflammation, rash, eye inflammation, aseptic meningitis and sensorineural…
Abstract Number: 802 • 2019 ACR/ARP Annual Meeting
Canakinumab Improves Patient-Reported Outcomes in Patients with Recurrent Fever Syndromes: Results from a Phase 3 Trial
Helen Lachmann¹, Bernard Lauwerys ², Paivi Miettunen ³, Tilmann Kallinich ⁴, Annette Jansson ⁵, Itzhak Rosner ⁶, Raffaele Manna ⁷, Saramaria Murias ⁸, Sinisa Savic ⁹, Serge Smeets ¹⁰, Fabrizio De Benedetti ¹¹ and Anna Simon ¹², ¹The Royal Free Hospital & University College London, London, United Kingdom, ²Université catholique de Louvain, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, ³Alberta Children's Hospital, Calgary, ON, Canada, ⁴Charite, Berlin, Germany, ⁵Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-University, Munich, Germany, ⁶Bnei Tzion, Haifa, Israel, ⁷Università Cattolica del Sacro Cuore, Rome, Lazio, Italy, ⁸University Hospital La Paz, Madrid, Madrid, Spain, ⁹St James’s University Hospital, Leeds, England, United Kingdom, ¹⁰Novartis, Amsterdam, Netherlands, ¹¹Bambino Gesù Children’s Hospital, Rome, Italy, ¹²Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Recurrent fever syndromes have a significant impact on health-related quality of life (HRQoL).1 Canakinumab (CAN) has demonstrated efficacy and safety in patients with colchicine-resistant…
Abstract Number: 803 • 2019 ACR/ARP Annual Meeting
Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment
Kenan Barut ¹, Amra Adrovic ², Sezgin Sahin ³, Mehmet Yıldız ², Oya Koker ², Gamze Yalcin ², Omer Faruk Beser ⁴, Bekir Kocazeybek ⁵, Pelin Yuksel ⁵ and Ozgur Kasapcopur⁶, ¹Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, İstanbul, Istanbul, Turkey, ²Department of Pediatric Rheumatology, Istanbul University Cerrahpasa, Istanbul, Istanbul, Turkey, ³Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, ⁴Department of Pediatrics, Okmeydani Education and Training Hospital, Istanbul, Istanbul, Turkey, ⁵Department of Microbiology, Istanbul University Cerrahpasa, Istanbul, Istanbul, Turkey, ⁶Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Autoimmune, autoinflammatory mechanism and drugs used in treatment increase the risk of liver disease in patients with chronic rheumatic diseases. Hepatitis A vaccine is…
Abstract Number: 804 • 2019 ACR/ARP Annual Meeting
STING-associated Vasculopathy with Onset in Infancy (SAVI Syndrome) Can Mimic Juvenile Idiopathic Arthritis
Jose Luis Tandaipan¹, Mireia Lopez Corbeto ² and Estefania Moreno Ruzafa ³, ¹Hospital Universitari Mutua Terrassa, Terrassa, Spain, ²Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain, ³Hospital Universitari Vall d'Hebron, Barcelona, Spain
Background/Purpose: Gain-of-function mutations in TMEM173 encoding STING (Stimulator of Interferon Genes) underlie a novel type I INF termed SAVI syndrome. It is characterized by a…
Abstract Number: 805 • 2019 ACR/ARP Annual Meeting
Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities
Shivani Garg¹, Christie Bartels ¹, Cristina Drenkard ², Gaobin Bao ² and S Sam Lim ², ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Emory University, Atlanta, GA
Background/Purpose: SLE is an independent risk factor for premature cardiovascular disease (CVD) and afflicts African Americans (AA’s) 3 times more than whites. Two predominantly white…
Abstract Number: 806 • 2019 ACR/ARP Annual Meeting
A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease
Rona Smith¹, David Jayne ² and Peter Merkel ³, ¹University of Cambridge, Cambridge, England, United Kingdom, ²Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia
Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and relapse rates…
Abstract Number: 807 • 2019 ACR/ARP Annual Meeting
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Atul Deodhar¹, Philip Helliwell ², Wolf-Henning Boencke ³, Elizabeth Hsia ⁴, Alexa Kollmeier ⁵, Ramanand Subramanian ⁵, Xie Xu ⁵, Shihong Sheng ⁵, Bei Zhou ⁵ and Christopher Ritchlin ⁶, ¹Oregon Health & Science University, Portland, OR, ²University of Leeds, Leeds, United Kingdom, ³Geneva Univ Hospitals, Geneva, Switzerland, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY
Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved to treat PsO. We evaluated GUS efficacy and safety in a Phase 3, double-blind, PBO-controlled trial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].